MediWound Ltd. MDWD
MediWound Ltd. (Nasdaq: MDWD) is a dermatology drug developer. Its lead program, NexoBrid, is in Phase 3 for enzymatic eschar removal in deep partial- and full-thickness thermal burns. Its next catalyst on record is EscharEx: Initiate Phase II study in diabetic foot ulcers (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EscharEx — Initiate Phase II study in diabetic foot ulcers (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NexoBrid | eschar removal in thermal burns | biologic-other | Approved |
| EscharEx (VALUE) | debridement of venous leg ulcers | biologic-other | Phase 3 |
| MW005 | basal cell carcinoma | unclear | Phase 2 |
| EscharEx | debridement of diabetic foot ulcers | biologic-other | Pre-clinical |
| EscharEx head-to-head vs SANTYL | venous leg ulcers | biologic-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.